Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
The Lancet Oncology2018Vol. 19(3), pp. 310–322
Citations Over TimeTop 1% of 2018 papers
Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, Carmen Mak, Daniel Wang, Raghunath Rajat, John Park, Lauren E. Haydu, Christine N. Spencer, Matthew Wongchenko, Stephen Lane, Yong Sang Lee, Mathilde Kaper, Meredith McKean, Kathryn E. Beckermann, Samuel M. Rubinstein, Isabelle Rooney, Luna Musib, Nageshwar Budha, Jessie J. Hsu, Theodore S. Nowicki, Alexandre Avila, T Haas, Mäneka Puligandla, Charles Lee, Shenying Fang, Jennifer A. Wargo, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, Paul B. Chapman, Jeffrey A. Sosman, Dirk Schadendorf, Jean‐Jacques Grob, Keith T. Flaherty, Damian Walker, Yibing Yan, Edward McKenna, Jeffrey J. Legos, Matteo S. Carlino, Antoni Ribas, John M. Kirkwood, Georgina V. Long, Douglas B. Johnson, Alexander M. Menzies, Michael A. Davies
Related Papers
- → Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung(2018)8 cited
- → Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib(2017)11 cited
- → Vemurafenib vs. Combination Dabrafenib/Trametinib(2014)
- Фармакоэкономический анализ применения вемурафениба и дабрафениба у пациентов с неоперабельной или метастатической меланомой с мутацией BRAF V600(2017)